Skip to main content
NCBI home page
Proceedings of the Royal Society of Medicine logoLink to Proceedings of the Royal Society of Medicine
. 1960 Nov;53(11):930–934. doi: 10.1177/003591576005301108

An Experiment with a Psychiatric Night Hospital

Joshua Bierer, Ivor W Browne
PMCID: PMC1871082  PMID: 19994080

Full text

PDF
930

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BUSCH A. K., JOHNSON W. C. L.S.D. 25 as an aid in psychotherapy; preliminary report of a new drug. Dis Nerv Syst. 1950 Aug;11(8):241–243. [PubMed] [Google Scholar]
  2. FISCHER R., GEORGI F., WEBER R. Psychophysische Korrelationen. VIII. Modellversuche zum Schizophrenieproblem: Lysergsäurediäthylamid und Mezcalin. Schweiz Med Wochenschr. 1951 Aug 25;81(34):817–contd. [PubMed] [Google Scholar]
  3. FORRER G. R., GOLDNER R. D. Experimental physiological studies with lysergic acid diethylamide (LSD-25). AMA Arch Neurol Psychiatry. 1951 May;65(5):581–588. doi: 10.1001/archneurpsyc.1951.02320050038004. [DOI] [PubMed] [Google Scholar]
  4. FREDERKING W. Intoxicant drugs (mescaline and lysergic acid diethylamide) in psychotherapy. J Nerv Ment Dis. 1955 Mar;121(3):262–266. doi: 10.1097/00005053-195503000-00010. [DOI] [PubMed] [Google Scholar]
  5. LIDDELL D. W., WEIL-MALHERBE H. The effects of methedrine and of lysergic acid diethylamide on mental processes and on the blood adrenaline level. J Neurol Neurosurg Psychiatry. 1953 Feb;16(1):7–13. doi: 10.1136/jnnp.16.1.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. MAYER-GROSS W., McADAM W., WALKER J. W. Psychological and biochemical effects of lysergic acid diethylamide. Nature. 1951 Nov 10;168(4280):827–828. doi: 10.1038/168827b0. [DOI] [PubMed] [Google Scholar]
  7. OLTMAN J. E., McGARRY J. J., FRIEDMAN S. Parental deprivation and the broken home in dementia praecox and other mental disorders. Am J Psychiatry. 1952 Mar;108(9):685–694. doi: 10.1176/ajp.108.9.685. [DOI] [PubMed] [Google Scholar]
  8. PARIS R., BEAUQUESNE L. Les dérivés flavoniques. Ann Pharm Fr. 1950 Mar;8(3):228–236. [PubMed] [Google Scholar]
  9. RINKEL M., DeSHON H. J., HYDE R. W., SOLOMON H. C. Experimental schizophrenia-like symptoms. Am J Psychiatry. 1952 Feb;108(8):572–578. doi: 10.1176/ajp.108.8.572. [DOI] [PubMed] [Google Scholar]
  10. SANDISON R. A., SPENCER A. M., WHITELAW J. D. The therapeutic value of lysergic acid diethylamide in mental illness. J Ment Sci. 1954 Apr;100(419):491–507. doi: 10.1192/bjp.100.419.491. [DOI] [PubMed] [Google Scholar]
  11. SANDISON R. A., WHITELAW J. D. Further studies in the therapeutic value of lysergic acid diethylamide in mental illness. J Ment Sci. 1957 Apr;103(431):332–343. doi: 10.1192/bjp.103.431.332. [DOI] [PubMed] [Google Scholar]
  12. SAVAGE C. Lysergic acid diethylamide; a clinical-psychological study. Am J Psychiatry. 1952 Jun;108(12):896–900. doi: 10.1176/ajp.108.12.896. [DOI] [PubMed] [Google Scholar]
  13. SLOANE B., DOUST J. W. Psychophysiological investigations in experimental psychoses; results of the exhibition of d-lysergic acid diethylamide to psychiatric patients. J Ment Sci. 1954 Jan;100(418):129–144. doi: 10.1192/bjp.100.418.129. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press

RESOURCES